Information from one of our medical advisors, Professor J Larkin.

The Royal Marsden has  just opened the above study which is basically one  year of adjuvant Pembrolizumab for thick primary (greater than 4mm not ulcerated or greater than 2mm and ulcerated) melanomas, with negative SNB and is similar in principle to Keynote 054 for Stage 3.

UK centres are Manchester, Cambridge, Guys and the Marsden, all of these centres would of course be delighted to see any potentially suitable patients.

Any patients who need further information, please contact your treating team, or let us know how we can help.